TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00124293
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04204603
Drug: CKD-506
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT03758924
Drug: ANAVEX2-73
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution
Study: NCT02396628
Drug: Experimental intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
Study: NCT01831479
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of olmesartan 40mg tablet QD for 7 consecutive days
Study: NCT01279213
Drug: paliperidone clozapine
Normalized name: Paliperidone
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Study: NCT02864030
Drug: ERIBULIN MESYLATE
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin.
Study: NCT04227704
Drug: Ketamine 50 MG/ML
Normalized name: ketamine 50 MG/ML
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
Study: NCT04227704
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 0.9% Sodium Chloride (N/S)
Study: NCT00695032
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00695032
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02760277
Drug: Vamorolone 0.25 mg/day/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Study: NCT02760277
Drug: Vamorolone 0.75 mg/day/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Study: NCT02760277
Drug: Vamorolone 2.0 mg/day/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Study: NCT02760277
Drug: Vamorolone 6.0 mg/day/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Study: NCT02880540
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02880540
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002888
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002888
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04501211
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal sancuso patch
Study: NCT03103451
Drug: BCD-121
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02117258
Drug: Z-360
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
Study: NCT00799071
Drug: posaconazole (PSZ)
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
Study: NCT00978627
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
Study: NCT00978627
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
Study: NCT00978627
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
Study: NCT05718466
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02247557
Drug: Liposome encapsulated BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
Study: NCT02247557
Drug: BOTOX 200U in normal saline
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
Study: NCT00905515
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain on cyclosporine at target trough level of 50-250 ng/mL.
Study: NCT00905515
Drug: Prograf (Tacrolimus)
Normalized name: tacrolimus Injection [Prograf]
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
Study: NCT03647488
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg (tablets) orally taken twice daily
Study: NCT03647488
Drug: Spartalizumab
Normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab 400 mg via intravenous infusion once every 28 days
Study: NCT03647488
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
Study: NCT03460678
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
Study: NCT03460678
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
Study: NCT01268163
Drug: Hospira Docetaxel Injection
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-100 mg/m\^2 IV
Study: NCT02559167
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
Study: NCT00174824
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00150423
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03046108
Drug: blind injection of Mepivacaine
Normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: blind injection of 1 cc of Mepivacaine Normon 2% ®
Study: NCT03046108
Drug: blind injection of Triamcinolone
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: blind injection of 40 mg of triamcinolone (trigon depot ®)
Study: NCT03046108
Drug: guided injection of mepivacaine
Normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
Study: NCT03046108
Drug: guided injection of Triamcinolone
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
Study: NCT03289429
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Study: NCT03289429
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Study: NCT03037931
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Iron
Study: NCT04764643
Drug: N-acetylcysteine solution
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Study: NCT04764643
Drug: sodium thiosulfate solution
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Study: NCT01834547
Drug: Drugs use: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablets
Study: NCT00606125
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
Study: NCT01834547
Drug: Drug use: modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg tablets
Study: NCT00534144
Drug: sodium ferric gluconate complex in sucrose injection
Normalized name: sodium ferric gluconate complex
DrugBank: Sodium ferric gluconate complex (DB09517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
Study: NCT03418896
Drug: human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single injection of a standard dose
Study: NCT03505034
Drug: Umbilical Cord Mesenchymal Stem Cells
Normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
Study: NCT00604786
Drug: omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Study: NCT02698436
Drug: 2.5% Benzoyl Peroxide Treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The BPO treatment is applied twice daily, once in the morning and once in the evening
Study: NCT03529422
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg IV every 3 weeks for 6 cycles
Study: NCT01621737
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 42 IU BID for six weeks
Study: NCT01621737
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 84 IU BID for six weeks
Study: NCT01663389
Drug: GSK1322322 1000 mg containing radioactive 14C-GSK1322322
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
Study: NCT01663389
Drug: GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
Study: NCT04478617
Drug: Metronidazole Vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
Study: NCT01516138
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Study: NCT00913341
Drug: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913341
Drug: Alprazolam Tablets, 1 mg (The Upjohn Company)
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03147404
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
Study: NCT00909337
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x62.5mg for 4 weeks, then 2x125mg
Study: NCT00910689
Drug: Propranolol or nadolol
Normalized name: Nadolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
Study: NCT00032773
Drug: pentostatin for injection
Normalized name: Pentostatin for Injection
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01103323
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study: NCT03791905
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy drug
Study: NCT03791905
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy drug
Study: NCT03791905
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy drug
Study: NCT03791905
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy drug
Study: NCT03221023
Drug: Vancomycin Hydrochloride
Normalized name: Vancomycin Hydrochloride
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
Study: NCT03221023
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals in the control arm will receive intrawound saline solution
Study: NCT00551590
Drug: Sitagliptin tablet
Normalized name: Sitagliptin Tablets
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg PO for three days.
Study: NCT00551590
Drug: Exendin(9-39) infusion
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin(9-39) IV on two consecutive study days.
Study: NCT02343224
Drug: Pegylated interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
Study: NCT01081353
Drug: Aspirin Migraine
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One effervescent tablet under fasting conditions
Study: NCT00071747
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618527
Drug: mycophenolate mofetil (Cellcept)
Normalized name: MYCOPHENOLATE MOFETIL (CELLCEPT) 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gram po, bid
Study: NCT00618527
Drug: human interferon beta 1a (Rebif)
Normalized name: Interferon beta-1a (recombinant human)
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44mcg sq injection every other day
Study: NCT03339700
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
Study: NCT03339700
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
Study: NCT00098332
Drug: forodesine hydrochloride
Normalized name: Forodesine hydrochloride
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00189488
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an intravenous (IV) bolus.
Study: NCT01081353
Drug: Aspirin Aspro
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One effervescent tablet under fasting conditions
Study: NCT02145234
Drug: BMS-986089
Normalized name: Bms-986089 (fully human anti-myostatin adnectin)
DrugBank: Talditercept alfa (DB16337)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02145234
Drug: Placebo matching with BMS-986089
Normalized name: Bms-986089 (fully human anti-myostatin adnectin)
DrugBank: Talditercept alfa (DB16337)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02900742
Drug: Gemcitabine®
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.
Study: NCT02900742
Drug: Pemetrexed®
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.
Study: NCT02900742
Drug: Docetaxel®
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
Study: NCT00507195
Drug: Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00119210
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00197587
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
Study: NCT04210193
Drug: ALK Alutard 5-grasses
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
Study: NCT04210193
Drug: ALK Diluent
Normalized name: DILUENT
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL of ALK Diluent as an intralymphatic injection
Study: NCT00324714
Drug: risedronate sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02259647
Drug: Sorafenib 400mg twice daily + intravenous infusion ofVit K1
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month